Aptahem AB (publ) (NGM:APTA)
Sweden · Delayed Price · Currency is SEK 1.095
-0.065 (-5.60%)
At close: Jul 18, 2025
Aptahem AB Company Description
Aptahem AB (publ), a biotechnology company, develops and sells aptamer-based pharmaceuticals for the treatment of acute life-threatening conditions.
The company’s lead products candidate is Apta-1, which is in preclinical stage to prevent the onset of life-threatening organ and tissue damage in sepsis patients.
It has collaborations with various academic groups, including Consortium with Orebro University, Seattle Children’s Research Institute, and University Health Network.
Aptahem AB (publ) was incorporated in 2014 and is based in Malmö, Sweden.
Aptahem AB (publ)
| Country | Sweden |
| Founded | 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 4 |
| CEO | Mikael Lindstam |
Contact Details
Address: Norra Vallgatan 58 Malmö, 211 22 Sweden | |
| Phone | 46 7 66 02 01 99 |
| Website | aptahem.com |
Stock Details
| Ticker Symbol | APTA |
| Exchange | Nordic Growth Market |
| Fiscal Year | January - December |
| Reporting Currency | SEK |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Mikael Lindstam | Co-Founder and Chief Executive Officer |
| Dr. Bert Junno | Co-Founder and Chairman |
| Dr. Kjell G. Stenberg | Chief Marketing Officer and Pres |
| Luiza Jedlina | Co-Founder and CSO |
| Ola Skanung | Chief Financial Officer |
| Maria Ekblad | Chief Operating Officer |
| Ulf Bjorklund M.Sc. | Senior Executive Advisor |
| Ingela Hallberg | Chief Medical Officer |